<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02937974</url>
  </required_header>
  <id_info>
    <org_study_id>WK-2016-HR-02</org_study_id>
    <secondary_id>Chinese PLA General Hospital</secondary_id>
    <nct_id>NCT02937974</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD</brief_title>
  <official_title>Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD：a Multicentre Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Hospitals affiliated to the China PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Navy General Hospital，Chinese People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rocket Force General Hospital，Chinese People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>307 Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Shijitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: A prospective multicenter randomized controlled trial to assess the efficacy and
      safety of Xuebijing injection for acute exacerbation of chronic obstructive pulmonary
      disease(AECOPD).

      Methods: 254 AECOPD inpatients will be recruited in 6 hospitals in China over 2 years. They
      will be randomly assigned to Experimental group and Placebo group，Experimental: Xuebijing
      injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the
      agent for consecutive 5 days；Placebo Comparator: Normal Saline 150ml IV, in 80mins, per 12
      hours. administration of the agent for consecutive 5 days. Compare the following index
      between the two groups: Invasive mechanical ventilation rate, length of hospital stay, Treg
      cell,Th1,Th2,HLA-DR,CRP,PCT,IL-4,IL-6,IL-10,TNF-α，IFN-γ, APACHEⅡ, CAPS score.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective multicenter randomized controlled trial to assess the efficacy and safety of
      Xuebijing injection for acute exacerbation of chronic obstructive pulmonary disease(AECOPD).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Invasive mechanical ventilation rate</measure>
    <time_frame>28 days</time_frame>
    <description>Invasive mechanical ventilation rate in %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>length of Hospital stay</measure>
    <time_frame>28 days</time_frame>
    <description>Invasive mechanical ventilation rate in days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">254</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Xuebijing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xuebijing</intervention_name>
    <description>Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days</description>
    <arm_group_label>Xuebijing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Body weight≥40kg and ≤100kg

          2. Diagnosis of COPD :(following Global initiative for Chronic Obstructive Lung
             Disease，GOLD2016)

          3. Forced Expiratory Volume in 1 second of less than 70% predicted value after
             bronchodilator

          4. Acute exacerbation of COPD: the clinical presentation of the patient complaining of an
             acute change of symptoms(baseline dyspnea,cough,and/or sputum production)that is
             beyond normal day-to-day variation.

          5. Assessment of COPD Exacerbations: Medical History:severity of COPD based on degree of
             airflow limitation;Duration of worsening or new symptoms;Number of previous episodes
             (total/hospitalizations); Comorbidities; Present treatment regimen;Previous use of
             mechanical ventilation;

          6. sign the informed consent

        Exclusion Criteria:

          1. Pregnant women, lactating women；

          2. Be allergic to Xuebijing；

          3. Acute exacerbation of COPD onset of more than 72 hours；

          4. AECOPD with severe hypoxemia：oxygenation index &lt;150 or received Endotracheal
             intubation invasive mechanical ventilation；

          5. Participation in another experimental protocol within 30 days of study entry

          6. Primary diseases：Asthma，Cystic fibrosis，Lung cancer，Tuberculosis，Pulmonary
             sarcoidosis，Pulmonary interstitial fibrosis，Malignant neoplasms，Blood system
             diseases，HIV；

          7. Complications：Pulmonary embolism，shock，DIC，Unstable cardiovascular disease，Upper
             gastrointestinal bleeding，pneumothorax，Severe liver and kidney dysfunction；

          8. Mental incompetence or active psychiatric illness

          9. used the following drugs within 72 hours days of study entry：Ulinastatin，Tanreqing，
             Reduning，Qingkailing；

         10. The investigator judged that the subject could not be completed or should not
             participate in the trial：Hemodialysis more than 1 mouth，Organ transplant patients with
             potential medical dispute.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lixin Xie, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/?term=19729666</url>
    <description>19729666</description>
  </link>
  <reference>
    <citation>Freeman CM, Martinez FJ, Han MK, Ames TM, Chensue SW, Todt JC, Arenberg DA, Meldrum CA, Getty C, McCloskey L, Curtis JL. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Dec 15;180(12):1179-88. doi: 10.1164/rccm.200904-0552OC. Epub 2009 Sep 3.</citation>
    <PMID>19729666</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Lixin Xie</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Disease, Chronic Obstructive</keyword>
  <keyword>Xuebijing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

